Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults

Trial Profile

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Oct 2008 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Actual patient number (420) added as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top